Circle Wealth Management LLC Buys 1,161 Shares of Zoetis Inc. (NYSE:ZTS)

Circle Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 100.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,322 shares of the company’s stock after acquiring an additional 1,161 shares during the quarter. Circle Wealth Management LLC’s holdings in Zoetis were worth $502,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Rafferty Asset Management LLC boosted its holdings in shares of Zoetis by 4.4% during the 4th quarter. Rafferty Asset Management LLC now owns 19,645 shares of the company’s stock worth $4,794,000 after buying an additional 832 shares during the period. Confluence Wealth Services Inc. bought a new stake in Zoetis in the 4th quarter valued at about $315,000. JPMorgan Chase & Co. boosted its holdings in Zoetis by 6.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,274,762 shares of the company’s stock valued at $311,079,000 after purchasing an additional 74,169 shares during the period. Rhumbline Advisers raised its position in shares of Zoetis by 1.0% in the 4th quarter. Rhumbline Advisers now owns 897,709 shares of the company’s stock valued at $219,068,000 after buying an additional 8,849 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Zoetis by 8.8% in the 4th quarter. International Assets Investment Management LLC now owns 1,548 shares of the company’s stock valued at $378,000 after buying an additional 125 shares in the last quarter. Institutional investors own 91.05% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $164.31 on Friday. The company has a 50 day simple moving average of $170.78 and a 200 day simple moving average of $175.69. The stock has a market cap of $76.92 billion, a price-to-earnings ratio of 37.26, a P/E/G ratio of 2.87 and a beta of 0.77. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.18 and a quick ratio of 1.46.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same quarter in the prior year, the company earned $1.19 earnings per share. Zoetis’s revenue for the quarter was up 7.8% compared to the same quarter last year. Research analysts anticipate that Zoetis Inc. will post 5.01 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 311 shares of the company’s stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total transaction of $55,980.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,501 shares of company stock worth $2,949,073. 0.12% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. Piper Sandler assumed coverage on shares of Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 target price for the company. Stifel Nicolaus dropped their target price on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. StockNews.com upgraded shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday. Finally, The Goldman Sachs Group lowered their price objective on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a research report on Thursday, July 21st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $224.00.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.